BIOMAT Database Logo BIOMAT Database Logo

Pirenzepine in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study. 1986

S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin

The efficacy of 50 mg pirenzepine twice daily in the treatment of reflux oesophagitis was compared with that of placebo in 47 patients over a period of 12 weeks. The 23 patients receiving pirenzepine experienced decreases in symptoms after 4 weeks (p less than 0.001) and 12 weeks (p less than 0.02) of treatment significantly greater than those in the 24 patients receiving placebo. The decreases in symptoms were associated with significantly less use of antacids by the pirenzepine group (p less than 0.01) during the first 4 weeks. Endoscopically, oesophagitis was healed or improved in 54.5% of patients receiving pirenzepine and in 18.2% of patients receiving placebo (p less than 0.05) after 4 weeks of treatment. After 12 weeks of treatment healing or improvement was seen in 55.0% and 35.0% of patients, respectively (difference not significant). Histologic improvement did not differ significantly between the groups. Our results suggest that pirenzepine is useful in the management of reflux oesophagitis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010890 Pirenzepine An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients. Gastrotsepin,Gastrozepin,L-S 519,LS-519,Piren-Basan,Pirenzepin,Pirenzepin Von Ct,Pirenzepin-Ratiopharm,Pirenzepine Dihydrochloride,Pyrenzepine,Ulcoprotect,Ulgescum,Dihydrochloride, Pirenzepine,LS 519,LS519,Piren Basan,Pirenzepin Ratiopharm,Von Ct, Pirenzepin
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004942 Esophagitis, Peptic INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM. Esophagitis, Reflux,Esophagitides, Peptic,Esophagitides, Reflux,Peptic Esophagitides,Peptic Esophagitis,Reflux Esophagitides,Reflux Esophagitis
D005260 Female Females
D005773 Gastroscopy Endoscopic examination, therapy or surgery of the interior of the stomach. Gastroscopic Surgical Procedures,Surgical Procedures, Gastroscopic,Gastroscopic Surgery,Surgery, Gastroscopic,Gastroscopic Surgeries,Gastroscopic Surgical Procedure,Gastroscopies,Procedure, Gastroscopic Surgical,Procedures, Gastroscopic Surgical,Surgeries, Gastroscopic,Surgical Procedure, Gastroscopic

Related Publications

S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Ranitidine in reflux oesophagitis. A double-blind placebo-controlled study.
January 1984, Digestion,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Prostaglandins in the treatment of reflux oesophagitis: double-blind placebo controlled clinical trial.
August 1991, Journal of the Royal College of Surgeons of Edinburgh,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study.
March 1986, Scandinavian journal of gastroenterology,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Ranitidine and placebo in the treatment of reflux oesophagitis. A double-blind randomized trial.
November 1983, The Medical journal of Australia,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Randomized, double-blind, placebo-controlled crossover trial of pirenzepine in patients with gastroesophageal reflux.
February 1992, Digestive diseases and sciences,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial.
January 1982, Scandinavian journal of gastroenterology. Supplement,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Long-term treatment of duodenal ulcer with pirenzepine. A double-blind, placebo-controlled trial.
January 1982, Scandinavian journal of gastroenterology. Supplement,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Treatment of reflux oesophagitis with a carbenoxolone/antacid/alginate preparation. A double-blind controlled trial.
November 1986, Scandinavian journal of gastroenterology,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study.
March 1995, The American journal of gastroenterology,
S Niemelä, and T Jääskeläinen, and J Lehtola, and J Martikainen, and I Krekelä, and S Sarna, and H Sarelin
Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group.
October 1992, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!